The frontiers

Regeneration, AI & beyond

The boldest idea is also the least mature: not to replace or retrain the vestibular system, but to regrow it — while data-driven tools sharpen how we diagnose along the way.

Regenerating the vestibular periphery

Vestibular hair cells, once lost, do not meaningfully regenerate in humans — the reason ablative loss is permanent. Two strategies aim to change that. Gene therapy delivers transcription factors (notably Atoh1) to coax supporting cells into becoming hair cells, with partial functional restoration in animal models. In parallel, stem-cell work has produced inner-ear organoids — miniature tissues with functional hair cells grown from human pluripotent stem cells — a platform for both study and, in principle, repair.1 Both are preclinical: no regenerative therapy is yet in vestibular clinical use, but the direction — restoration rather than compensation — is the most transformative in the field.

Blood biomarkers

A simple blood test for vestibular and central disease would change triage. The leading candidate is serum neurofilament light chain, a marker of axonal injury that correlates with disease activity in central disorders such as multiple sclerosis and is being explored to support diagnosis and monitoring.2 Markers of acute ischaemia are similarly under study for the stroke-versus-peripheral question.

Artificial intelligence & data

Machine-learning models trained on videonystagmography, video head-impulse, caloric and imaging data are learning to separate central from peripheral causes and to support triage with near-expert accuracy in research settings. AI is also being embedded in rehabilitation — adaptive, AI-driven VR that adjusts task difficulty to the patient in real time, and tele-platforms that monitor progress remotely.3 The promise is precision and access; the caveats are validation, generalisability and transparency before any of it guides real decisions.

Outlook

Taken together, the frontiers point toward a vestibular medicine that is more restorative (implants, regeneration), more precise (biomarkers, AI) and more accessible (tele-VR). The throughline of this chapter holds: judge each advance by its evidence and its readiness, and let the established tools — repositioning, rehabilitation, the disease-specific therapies — keep doing the heavy lifting until the frontier arrives.

Key points

  • Gene therapy (Atoh1) and stem-cell organoids aim to regenerate hair cells — preclinical so far.
  • Serum neurofilament light chain is an emerging biomarker of central vestibular disease.
  • AI can approach expert accuracy in separating central from peripheral causes and can personalise VR rehab.
  • The future is more restorative, precise and accessible — but readiness and validation come first.